Claim: The S100A2 has an expression that's reduced in many cancers along with being down-regulated in melanoma.
Evidence: Its expression is reduced in many types of cancer, thereby distinguishing the cancerous expression profile of the other proteins of the S100 group. It has been reported that S100A2 is downregulated in lung, kidney, prostate cancer and melanoma.